Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Common Equity (2016 - 2025)

Conmed (CNMD) has disclosed Common Equity for 16 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 7.31% year-over-year to $1.0 billion, compared with a TTM value of $1.0 billion through Dec 2025, up 7.31%, and an annual FY2025 reading of $1.0 billion, up 7.31% over the prior year.
  • Common Equity was $1.0 billion for Q4 2025 at Conmed, up from $1.0 billion in the prior quarter.
  • Across five years, Common Equity topped out at $1.0 billion in Q4 2025 and bottomed at $673.0 million in Q2 2022.
  • Average Common Equity over 5 years is $837.6 million, with a median of $792.9 million recorded in 2022.
  • The sharpest move saw Common Equity fell 9.61% in 2022, then rose 17.17% in 2024.
  • Year by year, Common Equity stood at $785.4 million in 2021, then decreased by 5.08% to $745.5 million in 2022, then rose by 11.89% to $834.2 million in 2023, then rose by 15.4% to $962.7 million in 2024, then grew by 7.31% to $1.0 billion in 2025.
  • Business Quant data shows Common Equity for CNMD at $1.0 billion in Q4 2025, $1.0 billion in Q3 2025, and $1.0 billion in Q2 2025.